Summary of the third quarter (2023-01-01 - 2023-03-31)
- Patient recruitment has begun for the Multiple Myeloma study
- Net sales amounted to MSEK 0,0 (0,0)
- Operating profit/loss amounted to MSEK -1,6 (-1,1)
-
Earnings per share*
SEK -0.08 (-0.06)
* Before and after dilution. Earnings per share: Profit for the period divided by the average number of shares 18,485,857. For the comparison period, the average number of shares was 18,485,857. Amounts in brackets refer to the corresponding period last year.
Summary of the nine-month period (2022-07-01 - 2023-03-31)
- Net sales amounted to MSEK 0,0 (0,0)
- Operating profit/loss amounted to MSEK -3,7 (-3,2)
-
Earnings per share*
SEK -0.19 (-0.20) - Cash and cash equivalents at the end of the period amounted to MSEK 27.1 (35,5)
* Before and after dilution. Earnings per share: Profit for the period divided by the average number of shares 18,485,857. For the comparison period, the average number of shares was 16,225,200.Amounts in brackets refer to the corresponding period last year.
CEO's comment
The application for clinical phase 1 study regarding OsteoDex's treatment of multiple myeloma was approved by the
The principal investigator (PI) is Dr Katarina Uttervall, MD, PhD,
Study material, GMP manufactured OsteoDex, is produced by Biovian OY,
Anders R Holmberg
CEO
Contact
This information is such information that
This report is an in-house translation of the original report in Swedish
Board of Directors
This report has not been reviewed by the Company's auditor.
Dag Hammarskjölds Väg 34A, Uppsala
Mailing address:
Box 389, 751 06 Uppsala
www.dextechmedical.com
https://news.cision.com/dextech/r/dextech-medical-ab-interim-report-july-1--2022---march-31--2023,c3760878
https://mb.cision.com/Main/11652/3760878/2021982.pdf
(c) 2023 Cision. All rights reserved., source